- ►annals.org [PDF] M Bower, T Powles, S Williams, TN Davis, M … - Annals of Internal Medicine, 2007 - Am Coll Physicians Background: HIV-associated multicentric Castleman disease is a rare
lymphoproliferative disorder with marked systemic symptoms attributed to
cytokine disarray. Many therapeutic approaches in small series of patients ... Cited by 26 - Related articles - BL Direct - All 6 versions
- ►jcojournal.org L Gerard, A Berezne, L Galicier, V Meignin, … - Journal of Clinical Oncology, 2007 - jcojournal.org Results At study entry, the median time from MCD diagnosis was 21 months. All
patients had stable disease on chemotherapy and were dependent on chemotherapy
for a median time of 13 months. The median CD4 cell count was 270 x 10 6 ... Cited by 23 - Related articles - All 5 versions
T Powles, J Stebbing, S Montoto, M Nelson, … - Blood, 2007 - ncbi.nlm.nih.gov 1: Blood. 2007 Dec 1;110(12):4132-3. Rituximab as retreatment for rituximab
pretreated HIV-associated multicentric Castleman disease. ... Cited by 13 - Related articles - BL Direct
J Stebbing, L Pantanowitz, F Dayyani, RJ … - American Journal of Hematology, 2008 - interscience.wiley.com Multicentric Castleman's disease (MCD), a relatively rare lymphoproliferative
disorder that presents with heterogenous symptoms including fevers, anemia, and
multifocal lymphadenopathy, is today most commonly observed in individuals ... Cited by 10 - Related articles - BL Direct - All 2 versions
A Casquero, A Barroso, ML Fernández … - Annals of hematology, 2006 - Springer Abstract Several approved therapies for multicentric Castleman disease (MCD)
cannot be uniformly applied due to intolerable side effects. There is also a
high percentage of recurrence of this disease despite treatment. Rituximab ... Cited by 20 - Related articles - BL Direct - All 4 versions
A Bestawros, R Michel, C Séguin, JP Routy - American Journal of Hematology, 2008 - interscience.wiley.com Multicentric Castleman's disease (MDC) is a rare herpesvirus-8-related
prelymphomatous condition that may develop in patients infected with human
immunodeficiency virus (HIV). Therapy for MCD is not well established and ... Cited by 7 - Related articles - BL Direct - All 2 versions
T Newsom-Davis, M Bower, A Wildfire, C … - Leukemia & lymphoma, 2004 - informahealthcare.com A 32-year-old HIV-1 positive man was diagnosed with Castleman's disease
following a long history of constitutional symptoms. Primary therapy with single
agent rituximab was associated with a near complete response. During this ... Cited by 30 - Related articles - BL Direct - All 5 versions
D Gholam, JM Vantelon, A Al-Jijakli, JH … - Annals of hematology, 2003 - Springer Abstract Multicentric Castleman's disease (MCD) is a rare systemic
lymphoproliferative disorder with too few patient series reported in the
literature to have a clear idea about the etiology, outcome and the best ... Cited by 19 - Related articles - BL Direct - All 4 versions
EM Ocio, FM Sanchez-Guijo, M Diez-Campelo, … - American journal of hematology, 2005 - interscience.wiley.com Multicentric Castleman disease (MCD) is an uncommon lymphoproliferative disorder
for which the best therapeutic option is not yet well established.
Immune-related disorders are rare complications of MCD. We report on an MCD ... Cited by 22 - Related articles - All 3 versions
M Ide, Y Kawachi, Y Izumi, K Kasagi, T Ogino - European journal of haematology, 2006 - interscience.wiley.com Abstract: Multicentric Castleman's disease (MCD) is an indolent
lymphoproliferative disorder. The pathogenesis of MCD has not been established,
and its treatment remains uncertain. Several authors have described the ... Cited by 18 - Related articles - BL Direct - All 5 versions
